Biomarkers for Early Diagnosis of Ovarian Carcinoma

Manasa, G.; Mascarenhas, Ronald J.; Shetti, Nagaraj P.; Malode, Shweta J.; Aminabhavi, Tejraj M.

doi:10.1021/acsbiomaterials.2c00390

Cited by 22 publications

(10 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As one of the most common but fatal gynecological cancers, ovarian cancer (OC) imposes a great burden to female health on a global scale [ 1 ]. OC has been dubbed the “silent killer” due to its asymptomatic characteristics until advanced stages [ 2 ]. OC is regarded as a heterogenous disease that encompasses at least five subtypes with distinct biological and molecular properties [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

lncRNA DARS-AS1 Modulates TSPAN1-Mediated ITGA2 Hypomethylation by Interaction with miR-194-5p Thus Promoting Ovarian Cancer Progression

Jun

Gao

Chen

et al. 2022

Stem Cells International

View full text Add to dashboard Cite

Objective. Ovarian cancer (OC) is usually called the “silent killer” due to its asymptomatic characteristics until advanced stages, thus being a significant threat to female health worldwide. In this work, we characterized an oncogenic DARS-AS1 role in OC. Methods. The aggressiveness behaviors of the OC cell model were examined by CCK-8 assay, transwell invasion assay, flow cytometry, and immunoblotting analysis of apoptosis-related proteins. Interactions of miR-194-5p with lncRNA DARS-AS1 or TSPAN1 and of TSPAN1 with ITGA2 were validated by using a luciferase activity assay and chromatin immunoprecipitation (ChIP) assay. Results. The OC cell model exhibited overexpressed lncRNA DARS-AS1 compared to normal cells. lncRNA DARS-AS1 knockdown led to reduced OC cell growth and metastasis while inducing the apoptosis in the OC cell model. lncRNA DARS-AS1 positively regulated TSPAN1 expression by binding with miR-194-5p and TSPAN1-mediated ITGA2 hypomethylation in OC cells. Further rescue function studies demonstrated that lncRNA DARS-AS1 affected OC cell viability, migration, invasion, and apoptosis ability by modulating miR-194-5p and TSPAN1 expressions. Conclusion. Our work demonstrates that lncRNA DARS-AS1 promotes OC progression by modulating TSPAN1 and ITGA2 hypomethylation by binding with miR-194-5p.

show abstract

Section: Introductionmentioning

confidence: 99%

lncRNA DARS-AS1 Modulates TSPAN1-Mediated ITGA2 Hypomethylation by Interaction with miR-194-5p Thus Promoting Ovarian Cancer Progression

Jun

Gao

Chen

et al. 2022

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…OC biomarkers can be detected quickly and accurately with electrochemical nanosensors in blood, urine, and saliva due to the sensitivity of the technology ( Manasa et al, 2022 ). Furthermore, the incorporation of NPs with electrochemical systems (such as magnetic NPs, gold NPs, and carbon nanotubes) offers highly sensitive enhancement and multipathing capabilities for locating and managing cancer biomarkers ( Mohammadpour-Haratbar et al, 2022 ).…”

Section: Nanotechnology Approaches For Diagnosis Of Ocmentioning

confidence: 99%

New trends in diagnosing and treating ovarian cancer using nanotechnology

Zhang

Ding

Zhang

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Ovarian cancer stands as the fifth most prevalent cancer among women, causing more mortalities than any other disease of the female reproductive system. There are numerous histological subtypes of ovarian cancer, each of which has distinct clinical characteristics, risk factors, cell origins, molecular compositions, and therapeutic options. Typically, it is identified at a late stage, and there is no efficient screening method. Standard therapies for newly diagnosed cancer are cytoreductive surgery and platinum-based chemotherapy. The difficulties of traditional therapeutic procedures encourage researchers to search for other approaches, such as nanotechnology. Due to the unique characteristics of matter at the nanoscale, nanomedicine has emerged as a potent tool for creating novel drug carriers that are more effective and have fewer adverse effects than traditional treatments. Nanocarriers including liposomes, dendrimers, polymer nanoparticles, and polymer micelles have unique properties in surface chemistry, morphology, and mechanism of action that can distinguish between malignant and normal cells, paving the way for targeted drug delivery. In contrast to their non-functionalized counterparts, the development of functionalized nano-formulations with specific ligands permits selective targeting of ovarian cancers and ultimately increases the therapeutic potential. This review focuses on the application of various nanomaterials to the treatment and diagnosis of ovarian cancer, their advantages over conventional treatment methods, and the effective role of controlled drug delivery systems in the therapy of ovarian cancer.

show abstract

“…Smoking and renal failure lead to significantly elevated HE4, which may falsely identify OC 13 . HE4 seems more reliable than CA125 with higher specificity in meta‐analyses, but none of them can meet the clinical requirement 14,15 . The risk of ovarian malignancy algorithm (ROMA) is a predictive model that combines serum level of CA125 and HE4 with patients' menopausal status; it can classify patients with ovarian tumors (OTs) as low or high risk.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of CA125, HE4, ROMA, and CPH‐I in identifying primary ovarian cancer

Luo

Cui

et al. 2023

J of Obstet and Gynaecol

View full text Add to dashboard Cite

To evaluate the ability of carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), and Copenhagen Index (CPH-I) to identify primary ovarian cancer (OC) from borderline and benign ovarian tumors (OTs) and explore ideal cutoff points. Methods: A total of 684 OTs containing 276 OC patients, 116 ovarian borderline OTs and 292 benign OTs patients who underwent surgery in our hospital were included. We retrospectively searched the results of CA125 and HE4 before patients' surgery from the hospital's electronic medical records system. ROMA and CPH-I were calculated according to their menopausal status and age, respectively. Diagnostic performance of these four were assessed by drawing receiver operating characteristic (ROC) curves. Results: CA125, HE4, ROMA, and CPH-I were all significantly higher in OC women compared with borderline OTs (p < 0.001), followed by benign OTs (p < 0.001). Area under the curves (AUCs) for distinguishing OC were 0.850 (0.818-0.882), 0.891 (0.865-0.916), 0.910 (0.888-0.933) and 0.906 (0.882-0.930), respectively, and the corresponding ideal cutoff values for CA125, HE4, ROMA, and CPH-I were 132.5, 68.6, 23.8, and 6.4, respectively. The difference between ROMA and CPH-I was not significant (p = 0.97), but both were higher than CA125 and HE4 (p < 0.05). HE4 showed a significantly higher AUC than CA125 (p < 0.05). For postmenopausal women, CA125 performed equivalently to ROMA (p = 0.73) and CPH-I (p = 0.91). Conclusions: In identifying patients with OC, ROMA and CPH-I outperformed single tumor marker. The diagnostic performance of HE4 was significantly higher than that of CA125. CA125 was more suitable for postmenopausal women. K E Y W O R D S carbohydrate antigen 125, Copenhagen index, human epididymis protein 4, ovarian cancer, risk of ovarian malignancy algorithm

show abstract

Biomarkers for Early Diagnosis of Ovarian Carcinoma

Cited by 22 publications

References 143 publications

lncRNA DARS-AS1 Modulates TSPAN1-Mediated ITGA2 Hypomethylation by Interaction with miR-194-5p Thus Promoting Ovarian Cancer Progression

lncRNA DARS-AS1 Modulates TSPAN1-Mediated ITGA2 Hypomethylation by Interaction with miR-194-5p Thus Promoting Ovarian Cancer Progression

New trends in diagnosing and treating ovarian cancer using nanotechnology

Diagnostic performance of CA125, HE4, ROMA, and CPH‐I in identifying primary ovarian cancer

Contact Info

Product

Resources

About